Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy. Ongoing research will determine if dinutuximab could be used earlier in treatment, in nonresponders to initial therapies, in combination with chemotherapy, or in other cancers.

Multiple myeloma (MM) patients mount suboptimal neutralizing antibodies (nAb) following 2-doses of SARS-CoV-2 mRNA vaccines. Currently circulating SARS-CoV-2 variants of concern (VOC) carry the risk of breakthrough infections. We evaluated immune recognition of current VOC including BA.1, BA.2 and BA.5 in 331 racially representative MM patients following 2 or 3 doses of mRNA vaccines. Third dose increased nAbs against WA1 in 82% but against BA variants in only 33-44% of patients. Vaccine-induced nAbs correlated with RBD-specific class-switched memory B cells. Vaccine-induced spike-specific T-cells were detected in patients without seroconversion and cross-recognized variant-specific peptides but were predominantly CD4+ T-cells. Detailed clinical/immunophenotypic analysis identified features correlating with nAb/B/T cell responses. Patients who developed breakthrough infections following 3 vaccine doses had lower live-virus nAbs, including against VOC. MM patients remain susceptible to SARS-CoV-2 variants following 3 vaccine doses and should be prioritized for emerging approaches to elicit variant-nAb and CD8+ T-cells.

No abstract

Stacy Diao provided study design, collected and analyzed data, and prepared the manuscript. E Dan Nichols provided study design, analyzed data, and reviewed and edited the manuscript. Courtney DiNardo and Marina Konopleva contributed patients, and reviewed and edited the manuscript.Jing Ning and Wei Qiao conducted statistical analysis, results interpretation, and reviewed and edited the manuscript. Abhishek Maiti reviewed and edited the manuscript. Adam J. DiPippo provided study design, collected and analyzed data, and reviewed and edited the manuscript.